Yifei Sanjie Formula or Placebo With Anlotinib as Second-Line or Above Treatment for Metastatic Non-Small-Cell Lung Cancer: Study Protocol for a Double-Blind, Placebo-Controlled Randomized Pilot Study.
Wenmin ChenJietao LinTing YangZe Xin ZhangLanting TaoZhiwei XiaoHanrui ChenXiangjun QiLingling SunYang CaoLi-Zhu LinPublished in: Integrative cancer therapies (2023)
The Ethics Committee of the First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine approved the study protocol (approval no.: K2020151, 2021/08/19). The study will also be supervised and managed by the Ethics Committee.
Keyphrases
- placebo controlled
- double blind
- study protocol
- phase iii
- clinical trial
- public health
- phase ii
- big data
- randomized controlled trial
- open label
- machine learning
- squamous cell carcinoma
- phase ii study
- drug administration
- small cell lung cancer
- healthcare
- global health
- emergency department
- artificial intelligence
- combination therapy
- replacement therapy
- smoking cessation
- human milk